Alexion has been working hard to flesh out is pipeline as well, snapping up Achillion Pharma, Syntimmune, Wilson Therapeutics and Portola and forging an alliance with gene-silencing specialist ...
Alexion Pharmaceuticals’ ravulizumab for the prevention of delayed graft function after renal transplantation was granted FDA orphan ...
Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...
Alexion is a somewhat unique pharma company in that it focuses almost entirely on rare diseases – and although this is an immensely challenging area to operate in, the company’s senior vice ...
Hosted on MSN1y
FDA grants approval for Alexion’s NMOSD treatmentAstraZeneca recently entered an agreement to acquire Fusion Pharmaceuticals for up to $2.4bn in a strategic move to expand its portfolio. "FDA grants approval for Alexion’s NMOSD treatment" was ...
© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...
Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved ...
Hosted on MSN4mon
Pharmaceutical giant addresses critical health issue by rethinking its delivery trucks: 'Another milestone'To address this impact, pharmaceutical giant Alexion is partnering with global transportation company DHL to incorporate alternative fuels into its fleet. An article from Irish Tech News discussed ...
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing medicines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results